Bufezolac
| Code | Size | Price |
|---|
| TAR-T30609-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Bufezolac is a bioactive chemical.
CAS:
50270-32-1
Formula:
C21H22N2O2
Molecular Weight:
334.419
Purity:
0.98
SMILES:
CC(C)Cn1nc(c(c1CC(O)=O)-c1ccccc1)-c1ccccc1
References
1. Miao L, Shiraishi R, Fujise T, Kuroki T, Kakimoto T, Sakata Y, Takashima T, Iwakiri R, Fujimoto K, Shi R, Li X. Chemopreventive effect of mofezolac on beef tallow diet/azoxymethane-induced colon carcinogenesis in rats. Hepatogastroenterology. 2011 Jan-Feb;58(105):81-8. PubMed PMID: 21510291.
2. Niho N, Kitamura T, Takahashi M, Mutoh M, Sato H, Matsuura M, Sugimura T, Wakabayashi K. Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. Cancer Sci. 2006 Oct;97(10):1011-4. PubMed PMID: 16984374.
3. Kitamura T, Kawamori T, Uchiya N, Itoh M, Noda T, Matsuura M, Sugimura T, Wakabayashi K. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis. 2002 Sep;23(9):1463-6. PubMed PMID: 12189188.
4. Goto K, Ochi H, Yasunaga Y, Matsuyuki H, Imayoshi T, Kusuhara H, Okumoto T. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat. 1998 Jul;56(4):245-54. PubMed PMID: 9777656.